The licensed product is a sialidase
Posted: Tue Feb 18, 2025 4:10 am
Fusion protein independently developed by Palleon, created by fusing human sialidase with human monoclonal antibody genes, designed to remove immunosuppressive sialic acid from the surface of immune cells and tumor cells. A Phase 12 clinical trial of the licensed product in patients with advanced cancer is being conducted by Palleon in the United States.
After the cooperation and licensing agreement is signed, the company plans to conduct clinical research on the licensed product combined with Hanlicon for the treatment of lupus nephritis.
Hanlicon is a rituximab independently developed by the company. It was approved greece phone number list by the National Medical Products Administration NMPA for marketing in China excluding Hong Kong, Macao and Taiwan in February 2019. As of the date of this announcement, the approved indications for Hanlicon include: 1 nonHodgkin's lymphoma, 2 chronic lymphocytic leukemia CLL, and 3 rheumatoid arthritis RA. This collaboration is expected to enhance the therapeutic effect of Hanlicon on autoimmune diseases with the help of licensed products.
It is reported that Palleon is a biotechnology company founded in the United States in 2015, and its CEO is Dr. James Broderick. Palleon is developing drugs that target carbohydratemediated immune regulation to treat cancer and autoimmune diseases.
After the cooperation and licensing agreement is signed, the company plans to conduct clinical research on the licensed product combined with Hanlicon for the treatment of lupus nephritis.
Hanlicon is a rituximab independently developed by the company. It was approved greece phone number list by the National Medical Products Administration NMPA for marketing in China excluding Hong Kong, Macao and Taiwan in February 2019. As of the date of this announcement, the approved indications for Hanlicon include: 1 nonHodgkin's lymphoma, 2 chronic lymphocytic leukemia CLL, and 3 rheumatoid arthritis RA. This collaboration is expected to enhance the therapeutic effect of Hanlicon on autoimmune diseases with the help of licensed products.
It is reported that Palleon is a biotechnology company founded in the United States in 2015, and its CEO is Dr. James Broderick. Palleon is developing drugs that target carbohydratemediated immune regulation to treat cancer and autoimmune diseases.